Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: In vitro evaluation

Munerah Alfadhel, Utsana Puapermpoonsiri, Steven J. Ford, Fiona J. McInnes, Christopher F. van der Walle

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) poses an infection risk and eradication during hospitalization is recommended. Bacteriophage therapy may be effective in this scenario but suitable nasal formulations have yet to be developed. Here we show that lyophilization of bacteriophages in 1ml of a viscous solution of 1-2% (w/v) hydroxypropyl methylcellulose (HPMC) with/without the addition of 1% (w/v) mannitol, contained in Eppendorf tubes, yields nasal inserts composed of a highly porous leaflet-like matrix. Fluorescently labeled bacteriophage were observed to be homogenously distributed throughout the wafers of the dried matrix. The bacteriophage titer fell 10-fold following lyophilization to 10(8)pfu per insert, then falling a further 100- to 1000-fold over 6 to 12months storage at 4°C. This compares well with a total dose of 6×10(5)pfu in 0.2ml liquid applied into the ear during a recent clinical trial in humans. The residual water content of the lyophilized inserts was reduced upon the addition of mannitol to HPMC, but this did not have any correlation to the lytic activity. Mannitol underwent a transition from its amorphous to crystalline state during exposure of the inserts to increasing relative humidities (as would be experienced in the nose), although this transition was suppressed by higher HPMC concentrations and the presence of buffer containing gelatin and bacteriophages. Our results therefore suggest that lyophilized inserts harboring bacteriophage selective for S. aureus may be a novel means for the eradication of MRSA resident in the nose.
LanguageEnglish
Pages280-7
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume416
Issue number1
Early online date13 Jul 2011
DOIs
Publication statusPublished - 15 Sep 2011

Fingerprint

Intranasal Administration
Nose
Bacteriophages
Staphylococcus aureus
Mannitol
Freeze Drying
Methicillin-Resistant Staphylococcus aureus
Accidental Falls
Gelatin
Humidity
Ear
Buffers
Hospitalization
In Vitro Techniques
Clinical Trials
Water
Infection
Hypromellose Derivatives

Keywords

  • bacteriophage
  • Staphylococcus aureus
  • nasal insert
  • lyophilization
  • hydroxypropyl methylcellulose

Cite this

Alfadhel, Munerah ; Puapermpoonsiri, Utsana ; Ford, Steven J. ; McInnes, Fiona J. ; van der Walle, Christopher F. / Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus : In vitro evaluation. In: International Journal of Pharmaceutics. 2011 ; Vol. 416, No. 1. pp. 280-7.
@article{dcd152342dcb402eb1d96ad0e0edfa10,
title = "Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: In vitro evaluation",
abstract = "Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) poses an infection risk and eradication during hospitalization is recommended. Bacteriophage therapy may be effective in this scenario but suitable nasal formulations have yet to be developed. Here we show that lyophilization of bacteriophages in 1ml of a viscous solution of 1-2{\%} (w/v) hydroxypropyl methylcellulose (HPMC) with/without the addition of 1{\%} (w/v) mannitol, contained in Eppendorf tubes, yields nasal inserts composed of a highly porous leaflet-like matrix. Fluorescently labeled bacteriophage were observed to be homogenously distributed throughout the wafers of the dried matrix. The bacteriophage titer fell 10-fold following lyophilization to 10(8)pfu per insert, then falling a further 100- to 1000-fold over 6 to 12months storage at 4°C. This compares well with a total dose of 6×10(5)pfu in 0.2ml liquid applied into the ear during a recent clinical trial in humans. The residual water content of the lyophilized inserts was reduced upon the addition of mannitol to HPMC, but this did not have any correlation to the lytic activity. Mannitol underwent a transition from its amorphous to crystalline state during exposure of the inserts to increasing relative humidities (as would be experienced in the nose), although this transition was suppressed by higher HPMC concentrations and the presence of buffer containing gelatin and bacteriophages. Our results therefore suggest that lyophilized inserts harboring bacteriophage selective for S. aureus may be a novel means for the eradication of MRSA resident in the nose.",
keywords = "bacteriophage, Staphylococcus aureus, nasal insert, lyophilization, hydroxypropyl methylcellulose",
author = "Munerah Alfadhel and Utsana Puapermpoonsiri and Ford, {Steven J.} and McInnes, {Fiona J.} and {van der Walle}, {Christopher F.}",
note = "Copyright {\circledC} 2011 Elsevier B.V. All rights reserved.",
year = "2011",
month = "9",
day = "15",
doi = "10.1016/j.ijpharm.2011.07.006",
language = "English",
volume = "416",
pages = "280--7",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
number = "1",

}

Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus : In vitro evaluation. / Alfadhel, Munerah; Puapermpoonsiri, Utsana; Ford, Steven J.; McInnes, Fiona J.; van der Walle, Christopher F.

In: International Journal of Pharmaceutics, Vol. 416, No. 1, 15.09.2011, p. 280-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus

T2 - International Journal of Pharmaceutics

AU - Alfadhel, Munerah

AU - Puapermpoonsiri, Utsana

AU - Ford, Steven J.

AU - McInnes, Fiona J.

AU - van der Walle, Christopher F.

N1 - Copyright © 2011 Elsevier B.V. All rights reserved.

PY - 2011/9/15

Y1 - 2011/9/15

N2 - Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) poses an infection risk and eradication during hospitalization is recommended. Bacteriophage therapy may be effective in this scenario but suitable nasal formulations have yet to be developed. Here we show that lyophilization of bacteriophages in 1ml of a viscous solution of 1-2% (w/v) hydroxypropyl methylcellulose (HPMC) with/without the addition of 1% (w/v) mannitol, contained in Eppendorf tubes, yields nasal inserts composed of a highly porous leaflet-like matrix. Fluorescently labeled bacteriophage were observed to be homogenously distributed throughout the wafers of the dried matrix. The bacteriophage titer fell 10-fold following lyophilization to 10(8)pfu per insert, then falling a further 100- to 1000-fold over 6 to 12months storage at 4°C. This compares well with a total dose of 6×10(5)pfu in 0.2ml liquid applied into the ear during a recent clinical trial in humans. The residual water content of the lyophilized inserts was reduced upon the addition of mannitol to HPMC, but this did not have any correlation to the lytic activity. Mannitol underwent a transition from its amorphous to crystalline state during exposure of the inserts to increasing relative humidities (as would be experienced in the nose), although this transition was suppressed by higher HPMC concentrations and the presence of buffer containing gelatin and bacteriophages. Our results therefore suggest that lyophilized inserts harboring bacteriophage selective for S. aureus may be a novel means for the eradication of MRSA resident in the nose.

AB - Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) poses an infection risk and eradication during hospitalization is recommended. Bacteriophage therapy may be effective in this scenario but suitable nasal formulations have yet to be developed. Here we show that lyophilization of bacteriophages in 1ml of a viscous solution of 1-2% (w/v) hydroxypropyl methylcellulose (HPMC) with/without the addition of 1% (w/v) mannitol, contained in Eppendorf tubes, yields nasal inserts composed of a highly porous leaflet-like matrix. Fluorescently labeled bacteriophage were observed to be homogenously distributed throughout the wafers of the dried matrix. The bacteriophage titer fell 10-fold following lyophilization to 10(8)pfu per insert, then falling a further 100- to 1000-fold over 6 to 12months storage at 4°C. This compares well with a total dose of 6×10(5)pfu in 0.2ml liquid applied into the ear during a recent clinical trial in humans. The residual water content of the lyophilized inserts was reduced upon the addition of mannitol to HPMC, but this did not have any correlation to the lytic activity. Mannitol underwent a transition from its amorphous to crystalline state during exposure of the inserts to increasing relative humidities (as would be experienced in the nose), although this transition was suppressed by higher HPMC concentrations and the presence of buffer containing gelatin and bacteriophages. Our results therefore suggest that lyophilized inserts harboring bacteriophage selective for S. aureus may be a novel means for the eradication of MRSA resident in the nose.

KW - bacteriophage

KW - Staphylococcus aureus

KW - nasal insert

KW - lyophilization

KW - hydroxypropyl methylcellulose

UR - http://www.scopus.com/inward/record.url?scp=80051803007&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2011.07.006

DO - 10.1016/j.ijpharm.2011.07.006

M3 - Article

VL - 416

SP - 280

EP - 287

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -